Research programme: drug repositioning and selection - Ore Pharmaceuticals/Solvay Pharmaeuticals
Latest Information Update: 01 Sep 2009
At a glance
- Originator Solvay Pharmaceuticals
- Developer Ore Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 01 Sep 2009 No development reported - Preclinical for Undefined indication in USA (unspecified route)
- 29 Aug 2007 Preclinical trials in Undefined indication in USA (unspecified route)